Treating acute lymphoblastic leukemia (ALL) involves prolonged multi-agent radio-chemotherapy.
Introduction
Acute lymphoblastic leukemia (ALL) is an aggressive hematopoietic malignancy characterized by rapid accumulation of lymphoblasts in the marrow with suppression of hematopoiesis (1). Children are treated with prolonged multi-agent radio-chemotherapy, achieving at least 80% long-term survival (2) , but this is associated with frequent late adverse effects including secondary malignancies, various chronic medical problems, psychological and cognitive impairments (3, 4) . While adults with ALL frequently obtain complete remission, most relapse with only a third surviving 5 years from diagnosis (2, 5) . Immunologically mediated graft versus leukemia (GvL) effects are responsible, in part, for improved outcomes in the minority of patients eligible for allogeneic HSCT (6) (7) (8) (9) (10) (11) (12) . Unfortunately, the benefits of GvL are difficult to separate from the detrimental effects of graft versus host disease (13) .
Thus, measures that reduce the intensity or duration of chemotherapy without compromising disease control would improve the quality of life for survivors of childhood ALL, while more potent therapies are required for curing adult ALL. ALL is amenable to immunotherapy as demonstrated by the effectiveness of GvL, consequently administering vaccines targeting residual leukemic cells remaining after induction chemotherapy may help achieve these goals.
Leukemia cells often harbor unique antigens with immunogenic potential. For instance, the presence of autologous CD8 + and CD4 + T-cell immune responses to peptides derived from the leukemia-specific antigen NPM1 mut has been shown in patients with AML (14) . The use of adjuvants or mechanisms that up-regulate cell-surface immune activation molecules, improve the intrinsic immunogenicity and therapeutic potential of leukemia cell vaccines (15) (16) (17) . Indeed, allogeneic HSCT recipients with advanced high-risk ALL and AML were shown to generate tumor specific responses and survive longer following treatment with autologous leukemia cells mixed with syngeneic skin fibroblasts expressing CD40L and IL-2 from adenoviral vectors (18) acute and chronic lymphomas (19) . Unfortunately, available immunotherapeutic technologies suffer from inefficient recognition and processing of tumor peptide(s), leading to suboptimal anti-tumor Tcell responses in-vivo (20) . These challenges limit the potential impact of current immune-based anticancer therapies.
Neoplastic transformation is associated with defects of cellular antiviral defenses allowing selective infection of cancer cells by diverse families of attenuated viruses (21) (22) (23) . Rhabdoviruses, such as the engineered VSVd51 with deletion at methionine-51 of the matrix protein, and MG1, a recombinant Maraba virus with cooperative attenuating mutations in its matrix protein (L123W) and glycoprotein (Q242R), complement the interferon signaling defects in cancer cells. These specific mutations attenuate virulence and increase their tropism towards malignant cells (24, 25) . Vesicular Stomatitis Virus (VSV) can be rendered incapable of spreading between cells by creating mutants with deletion of the viral glycoprotein gene (VSVΔG) required for final virion assembly and egress (26) .
The biology of these enveloped single stranded negative-sense RNA viruses has been reviewed (24) .
Infection of tumor cells by these oncotropic viruses initiates a chain of events causing peri-tumor inflammation, activation of natural killer cells, macrophage-mediated innate immune attack, as well as induction of adaptive anti-tumor immune responses (21, 27, 28) .
Rhabdoviruses are capable of infecting leukemia cells in-vitro, however viral replication is quite limited in these cells (29) . This hinders their use as direct cytolytic agents for treatment of ALL.
However, using immunocompetent murine models of ALL, we show that a vaccine composed of syngeneic leukemia cells infected ex-vivo with rhabdovirus (immunotherapy by Leukemia-Oncotropic Virus or iLOV) generates a potent and durable anti-leukemia effect that is specifically directed towards the leukemia cell used to produce this vaccine.
Research. 
Materials and Methods

Reagents
Blasticidin and Zeocin TM , used for VSVd51ΔG production, were purchased from Invitrogen (Carlsbad, CA). The toll-like receptor (TLR) 3 agonist polyinosinic-polycytidylic acid (poly I:C) and TLR4 agonist lipopolysaccharide (LPS) were purchased from Sigma Aldrich (St. Louis, MO). Antimouse CD40-APC, Propidium iodide, 7-AAD viability-staining solutions and Annexin V Apoptosis Detection Kit APC were obtained from eBioscience (San Diego, CA). Anti-mouse CD19-FITC, CD3-PE, CD4-PerCP, CD8-PerCPCy5.5, biotin anti-mouse CD252 (Ox40L), and PE-streptavidin were obtained from BD Bioscience (Franklin Lakes, NJ). 
Tumor cells
Oncotropic viruses
The rhabdoviruses, MG1 and VSVd51 were propagated in Vero cells and purified as previously typical signs of advanced leukemia such as hind-leg paralysis, focal tumor development, significant weight loss and/or respiratory distress.
Immunization and leukemic challenge
Immunization was performed by tail vein injection of 100 μL per mouse per dose of freshly prepared iLOV, an alternative vaccine or PBS. Vaccines were administered once weekly for 3 doses, 
Adoptive cell transfer
Under sterile conditions, single cell suspensions of splenocytes were prepared from donor spleens removed from iLOV immunized or naïve DBA/2 mice using gentleMACS Dissociator 
Bone marrow transplantation and vaccination
Eight-week-old DBA/2 mice received total body irradiation (TBI) using 2 fractions of 450 cGy given 2 hours apart. Under aseptic conditions, 10 8-week-old B6D2F1 donors, were intravenously infused into each TBI-treated recipient. On day 43, cohorts (n=5-6/group) of bone marrow transplantation (BMT) recipient DBA/2 mice and healthy B6D2F1 mice, received the first of 3 weekly iLOV vaccinations. On day 63, a leukemia challenge of 1x10 7 L1210 cells was administered to all mice, including parallel-unimmunized cohorts (n=5/group).
Additional cohorts of unimmunized TBI-treated DBA/2 and naïve B6D2F1 were euthanized at day 43 for enumeration of the major lymphocyte compartments by flow cytometry.
Flow cytometry
Leukemia cell infections were evaluated by flow cytometric analysis of 10,000 cells using analysis performed with Kaluza software version 1.1 (Beckman Coulter) and Cell Lab Quanta Analysis (Beckman Coulter).
Statistics
Survival curves were generated using product limit (Kaplan-Meier) method and comparisons were performed using log-rank (Mantel-Cox) test, all P values are two-tailed. Elsewhere, data presented as mean + SEM with significance determined by Welch's corrected T-test. Statistical significance was determined at level of P < 0.05. Analyses were performed using Prism 5 software (GraphPad Software, La Jolla CA).
Results
MG1 infects leukemia lines in-vitro but is ineffective in halting leukemia progression in-vivo
We first wished to explore whether mice with disseminated ALL could be successfully treated by systemic delivery of live oncotropic rhabdovirus. We first established that MG1 was able to infect and kill various murine and human leukemia cell lines in-vitro at low MOI (Fig. 1A, 1B, S2) . L1210 leukemia cells demonstrate considerable permissiveness to MG1 infection and result in efficient, rapid cytolysis yet virus production is modest over 24-40 hours incubation (Fig. 1C) . Next, a cohort of leukemia-bearing mice was given 1x10 8 pfu of MG1-eGFP daily every 3 days for 3 doses. This was unable to prevent disease progression (Fig. 1D ). Organs were recovered from all mice at endpoint. Fig. 2A) , confirming that iLOV was able to establish highly protective anti-tumor responses. However, when leukemic challenge was administered one day prior to the MG1-iLOV vaccination series, 100% of control mice succumbed to leukemia, whereas 50% of mice that received MG1-iLOV survived (Fig. 2B ), illustrating that iLOV is able to induce a protective effect even in the presence of early-disseminated leukemia. This incomplete protection is likely due to rapid growth of L1210 leukemia in this aggressive tumor model, which outstrips the development of anti-tumor responses.
To test whether the protective effects of iLOV were mediated through development of antitumor immunity, MG1-iLOV was administered to athymic nude or immunocompetent DBA/2 mice once weekly for 3 doses. Treated and untreated nude mice died from leukemia a median of 18 and 23 days respectively following injection of viable L1210 cells. In contrast, immunocompetent mice that received iLOV rejected L1210 cells (Fig. 3A) . To further examine the immune requirements of the host, a BMT model was employed. After receiving myeloablative TBI, DBA/2 mice were administered 
While NK-cells, CD3+/4+ T-cells and B-cells were similar in number between the groups; CD3+/8+ Tcells were significantly reduced in the BMT recipients (Fig 3B) . This depletion of cytotoxic Tlymphocytes (CTLs) was associated with a reduction in long-term protective immunity against a leukemic challenge by approximately 40% in a parallel cohort of iLOV-vaccinated BMT recipients (Fig 3B) . The additional control cohorts of unimmunized BMT recipients and unimmunized B6D2F1 mice all reached typical endpoints by day 28. In a separate experiment, we wished to examine the effect of adoptive splenocyte transfer from long-term iLOV-protected mice to naïve recipients. Accordingly, 17 mice that received MG1-iLOV and survived between 211-349 days following leukemic challenge were used as splenocyte donors. Pooled donor splenocytes were administered to 8 naïve DBA/2 recipients followed 7 days later by injection of viable L1210 cells. Long-term survival was observed in 63% of recipients, while control mice that received the same number of splenocytes from untreated donors were unable to reject leukemic challenge (Fig. 3C) . Collectively, these observations indicate an intact thymocyte compartment mediates the anti-leukemic protection afforded by iLOV and CTLs are critical for optimal effect.
To examine the strength of the immune response that develops following iLOV, cohorts of unimmunized and MG1-iLOV treated mice were challenged with increasing amounts of viable L1210 cells. The LD 50 of unimmunized mice was approximately 4.9x10 4 cells while the LD 50 for MG1-iLOV vaccinated mice was estimated to be 3.8x10 6 cells. Thus, iLOV was able to protect mice against an almost 100 fold larger inoculum of leukemia than would be spontaneously rejected by unimmunized mice (Fig. 3D) . The durability of such a response is particularly critical as the ability to prevent leukemic recurrence may wane over time. iLOV-treated mice that survived a primary leukemic challenge were administered a second L1210 leukemia challenge either 100, 134, or 255 days after initial L1210 challenge. The majority of mice were able to reject this additional leukemic challenge, but there may be a time-dependent decline in the ability to reject a late secondary leukemic challenge (Fig. 3E) .
The effectiveness of iLOV treatment was not limited to a single rhabdovirus, leukemic cell line or mouse strain. Survival following leukemic challenge was observed when animals were administered iLOV prepared using a different rhabdovirus -VSVd51, indicating that the protective effects were independent of the specific rhabdovirus (Supplemental Fig. S3 ). Similarly, mice survived an otherwise lethal challenge with EL4, a T lymphoma cell line, when MG1-iLOV prepared using these cells was used to vaccinate syngeneic C57BL/6 mice (Supplemental Fig. S4 ). To examine the specificity of the anti-tumor protection afforded by iLOV, two cohorts of B6D2F1 hybrid mice were administered 3 weekly doses of MG1-L1210 iLOV. One cohort was subsequently challenged with viable 1 x 10 7 L1210 cells while the other received 1 x 10 7 EL4 cells. Mice that received the L1210-based iLOV were protected from L1210 challenge, while survival of EL4 challenged mice was identical to unimmunized mice challenged with EL4 (Fig. 3F) . The specificity of the immune response was further examined using reciprocal immunization combinations of EL4-iLOV or L1210-iLOV in cohorts of both DBA/2 and C57BL/6 mice. To control for immune recognition of leukemia cells based on the MHC disparity alone, additional cohorts of C57BL/6 and DBA/2 mice were immunized with γ-IR L1210 or γ-IR EL4 cells respectively. All groups were subsequently challenged with viable leukemia cells syngeneic to the breed. Only mice that received iLOV produced using syngeneic leukemia cells were protected (Supplemental Figure S5) . Together, these observations suggest that iLOV induces anti-tumor immunity functionally restricted to the specific antigenic profile of the leukemic cell used to produce iLOV rather than commonly expressed leukemic antigens. 
Virus infection is critical to induction of iLOV-mediated anti-leukemic immunity
We examined whether the cellular and viral components of iLOV could be individually effective at inducing protective anti-tumor immunity. Mice administered 3 doses of γ-IR ex-vivo MG1 infected L1210 cells (iLOV) survived subsequent administration of an otherwise lethal dose of L1210 cells, while all mice that received γ-IR uninfected L1210 cells prior to leukemic challenge succumbed with median survival that was not significantly different from unimmunized mice that received the same leukemic challenge dose. Furthermore, the virus must infect the cell for iLOV to be effective as 3 weekly separate co-injections of γ-IR L1210 cells and MG1, or the administration of 3 weekly doses of γ-IR L1210 cells mixed with MG1 at room temperature for 1 hour prior to injection, were unable to prevent the lethality of a subsequent L1210 leukemia challenge (Fig. 4A) .
In-vitro, leukemic cells exposed to UV-inactivated MG1-eGFP virus did not express GFP nor developed cytopathology. In contrast, L1210 cells exhibit green fluorescence following in-vitro exposure to live spread-incompetent VSVd51ΔG-eGFP, and delayed cytolysis occurs as long as 72 hours after infection (Fig. 4B) . Immunization with iLOV produced by infection of L1210 cells with VSVd51ΔG protected 80% of mice from the lethal effects of subsequent L1210 challenge (Fig. 4C ), indicating that iLOV is effective even if the virus is incapable of fully completing its lifecycle.
Administration of iLOV produced with UV-inactivated MG1 prior to challenge with viable L1210 leukemia was unable to prevent death from fulminant leukemia in 80% of mice. iLOV preparations fixed with PFA after virus infection but immediately prior to γ-IR were capable of protecting immunized mice just as effectively as freshly produced, unfixed iLOV preparations (Fig. 4D) . PFAfixed iLOV preparations did not contain detectable viable MG1 in a standard plaque assay. Thus in this model, live rhabdovirus was used for the manufacturing of iLOV but it was not critical at the time of administration. Figure S6) . Mice that received 3 weekly injections of these TLR-agonist preparations succumbed to subsequent injection of L1210 cells, in contrast to mice that received MG1-iLOV (Fig. 5A) . Similarly, pulsed stimulation of host innate immunity by direct injection of either poly I:C or LPS concurrently with 3 weekly injections of γ-IR L1210 cells was also incapable of protecting animals from subsequent injection of viable L1210 cells (Fig. 5B) . The protective effects induced by injection of ex-vivo virus infected leukemia cells cannot be mimicked solely by the presence of apoptotic or necrotic cells that are contained in iLOV preparations (Fig. 5C ).
Apoptosis was induced in L1210 cells by UV irradiation (Supplemental Fig. S7A ) while parallel samples of L1210 were pressure disrupted into cellular necrosis (Supplemental Fig. S7B ). Cohorts of mice received 3 weekly injections of either MG1-iLOV, UV-irradiated apoptotic L1210, or pressuredisrupted necrotic L1210 followed by challenge of viable L1210 leukemia. Mice that received UVirradiated or pressure disrupted L1210 expired due to leukemia in contrast to the mice that received MG1-iLOV. Administration of 3 weekly injections of apoptotic or necrotic L1210 cells mixed with MG1 virus just prior to injection, were similarly ineffective (Fig. 5D, E) .
Pre-existing anti-viral immunity does not impair development of anti-leukemia immunity
We wondered whether pre-existing anti-viral immunity to the rhabdovirus component would 
immunity. Prior to receiving MG1, mice did not manifest serum virus-neutralizing antibody while the titer of MG1 neutralizing antibody was ≥ 1:800 in serum of mice 10 days following administration of virus. Three doses of MG1-iLOV were administered starting 18 days after MG1 injection. The survival of MG1 immunized mice was no different than a cohort of mice that received MG1-iLOV without preceding MG1 inoculation when challenged with 1x10 6 L1210 cells (Fig. 6A) . However, when L1210 challenge was increased 10 fold, mice immunized against MG1 prior to MG1-iLOV treatment had a significant survival advantage over mice that received MG1-iLOV treatment alone (Fig. 6B) . These results suggest iLOV efficacy is not dampened but indeed may be augmented following development of anti-viral immunity.
Discussion
We show that live attenuated rhabdoviruses are able to infect and kill leukemia cells in-vitro but are incapable of treating mice with established systemic leukemia. An alternative approach, injecting mice with γ-IR virus-infected leukemia cells, or iLOV, controls leukemic progression. This effect is mediated by development of a robust adaptive anti-tumor immunity, wherein CTLs are essential for optimal efficacy. The immune response is specifically directed against the cell used to produce iLOV.
It is longstanding, protecting the animal from repeat leukemic challenge more than 8 months following 
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